1777 studies found for:    myeloma
Show Display Options
Rank Status Study
1 Active, not recruiting Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: aMILs;   Biological: Allogeneic Myeloma Vaccine
2 Active, not recruiting
Has Results
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Myeloma Immunoglobulin Idiotype Vaccine;   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine Sulfate;   Drug: Methotrexate;   Biological: GMCSF (granulocyte macrophage colony stimulating factor);   Biological: GCSF (granulocyte colony stimulating factor)
3 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
4 Terminated
Has Results
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
5 Recruiting Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: TH-302;   Drug: TH-302 and bortezomib
6 Recruiting Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
Condition: Multiple Myeloma
Intervention:
7 Active, not recruiting Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Conditions: Cancer;   Myeloma;   Multiple Myeloma
Intervention: Drug: Bortezomib
8 Active, not recruiting A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study
Condition: Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: dexamethasone
9 Active, not recruiting A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: Siltuximab
10 Completed Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
Conditions: Multiple Myeloma and Plasma Cell Neoplasm;   Renal Failure
Interventions: Drug: chemotherapy;   Drug: dexamethasone;   Procedure: plasmapheresis
11 Recruiting Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Biological: Allogeneic Myeloma Vaccine;   Biological: Prevnar-13
12 Recruiting Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Condition: Multiple Myeloma
Intervention:
13 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
14 Completed
Has Results
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Ruxolitinib 25 mg;   Drug: Dexamethasone 40 mg
15 Recruiting Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Fludarabine
16 Completed High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: High-Dose Sequential Chemotherapy followed by ASCT
17 Unknown  Study of DNA Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Genetic: polymorphism analysis
18 Active, not recruiting Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib + Dexamethasone
19 Completed Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Conditions: Graft vs Host Disease;   Multiple Myeloma
Interventions: Drug: Myeloma Immunoglobulin Idiotype Vaccine-KLH;   Drug: GM-CSF
20 Active, not recruiting Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: pomalidomide

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years